Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning-the IG-IBD LIVE study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pugliese Daniela, Privitera Giuseppe, Cersullo Nicola, Bordekar Harsh, Crispino Federica, Mezzina Nicolò, Pellegrini Lucienne, Allocca Mariangela, Laterza Lucrezia, Viola Anna, Bertani Lorenzo, Soru Pietro, Scrivo Barbara, Barberio Brigida, Ricci Chiara, Balestrieri Paola, Daperno Marco, Pluchino Dario, Rizzello Fernando, Scribano Maria Lia, Sablich Renato, Pastorelli Luca, Manguso Francesco, Variola Angela, Di Sario Antonio, Grossi Laurino, Ribaldone Davide Giuseppe, Biscaglia Giuseppe, Buda Andrea, Mocci Giammarco, Viscido Angelo, Di Paolo Maria Carla, Onali Sara, Rodino' Stefano, Coletta Marina, Principi Mariabeatrice, Miranda Agnese, Amato Arnaldo, Bezzio Cristina, Petruzzellis Carlo, Mazzuoli Silvia, Festa Stefano, Sartini Alessandro, Checchin Davide, Fanigliulo Libera, Gallina Sara, Cesarini Monica, Bodini Giorgia, Stradella Davide, Spagnuolo Rocco, Guidi Luisa, Savarino Edoardo, Cappello Maria, Caprioli Flavio, Costa Francesco, Fries Walter, Scaldaferri Franco, Fiorino Gionata, Castiglione Fabiana, Massari Alessandro, Orlando Ambrogio, Armuzzi Alessandro
Аннотация
METHODS: The Long-term Italian Vedolizumab Effectiveness (LIVE) study is multicentric, ambispective, observational study enrolling 1111 IBD patients (563 Crohn's disease, CD, 542 ulcerative colitis, UC). Steroid-free clinical remission (SFCR) at 24 months was the primary endpoint. A XAI model (eXtreme Gradient Boosting, XGB) was applied to identify the main clinical predictors of SFCR and development of adverse events (AEs).
RESULTS: Rates of SFCR at 24 months were 31.6 % and 39.7 % in CD and UC patients, and 0.14 AEs per patient-year was recorded. On XGB analysis, previous exposure to anti-TNFα and older age were the most important drivers for the prediction of SFCR; lower baseline CRP levels and fewer comorbidities were the most important features associated with no development of AEs.
CONCLUSIONS: Vedolizumab is effective and safe in IBD patients. XAI yielded promising results in identifying the most important predictors of SFCR and development of AEs.